Blockade of a key cytokine for MDSCs function, IL10, restores immunosurveillance and improves survivalPeripheral blood ARG/IDO/IL10+ MDSCs are especially abundant in patients with advanced ovarian cancer and their depletion is a good prognostic factorBRCA-mutated patients have less MDSCs and more T CD*+ effectors than patients with wild BRCA copy in early stage HGSOC, what could explain partly the survival benefit in this group of patients. This evidence concerns the gene CTLA4 and ovarian carcinoma.